Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05824689 · ClinicalTrials.gov registry record
Fluoroquinolone Resistance Prevalence Study
A clinical trial, sponsored by Hackensack Meridian Health.
- Terminated
- Registry status
- 124
- Enrollment target
NCT05824689 is a clinical trial that was terminated before completion, run by Hackensack Meridian Health. The registered enrollment target is 124 participants.
The verdict
NCT05824689 was terminated before completion, sponsored by Hackensack Meridian Health.
- TERMINATED
- Registry status
- 124 participants
- Enrollment target
Study Summary
This is an exploratory study to determine the prevalence of fluoroquinolone resistance in patients receiving dose-intense melphalan with autologous peripheral blood stem cell (PBSC) transplantation in the treatment of multiple myeloma (MM). These data may be used in subsequent studies exploring the use of prophylaxis in this patient population.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2022-07-08 |
| Est. Completion | 2025-01-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05824689
The ClinicalTrials.gov registry entry for NCT05824689 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 124 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hackensack Meridian Health, which has 90 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT05824689 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05824689 about?
NCT05824689 is a clinical study titled "Fluoroquinolone Resistance Prevalence Study". This is an exploratory study to determine the prevalence of fluoroquinolone resistance in patients receiving dose-intense melphalan with autologous peripheral blood stem cell (PBSC) transplantation in the treatment of multiple myeloma (MM). These data may be used in subsequent studies exploring the...
What is the current status of trial NCT05824689?
This trial is currently terminated. The enrollment target is 124 participants. The study started on 2022-07-08. Estimated completion is 2025-01-15.
Who is sponsoring clinical trial NCT05824689?
This trial is sponsored by Hackensack Meridian Health, which has 90 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.